American Society of Cataract and Refractive Surgery Meeting

American Society of Cataract and Refractive Surgery Meeting

Issue: June 25, 2017
May 05, 2017
1 min watch

Avedro implements reimbursement pathway for cross-linking products

Issue: June 25, 2017
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

LOS ANGELES — Avedro has undertaken an initiative to secure coverage and support reimbursement for its cross-linking system for treatment of keratoconus and corneal disease.

“Our plan going forward is to expand the market for keratoconus,” Reza Zadno, president and CEO of Avedro, told during the Ophthalmology Innovation Summit here. Securing such reimbursement would advance that goal by allowing greater patient access to the treatment.

The KXL system, Photrexa 0.146% (riboflavin 5’-phosphate ophthalmic solution) and Photrexa Viscous 0.146% (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) are FDA approved for treatment of progressive keratoconus and corneal ectasia.

As part of the initiative, the company will launch the Avedro Reimbursement Customer Hub program, which will include a hotline, a patient assistance program and a prescription assistance program, according to a company press release.

Zadno said the company is also expanding into the refractive market but “not competing with LASIK.”

Disclosure: Zadno reports he is president and CEO of Avedro.